Novo Nordisk

Update in progress

NVO (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Novo Nordisk A/S develops, manufactures, and distributes pharmaceutical products through two segments: Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes Care segment provides diabetes, obesity, cardiovascular, and other therapies; Rare Disease covers rare blood and endocrine disorders and hormone replacement. It also offers smart insulin pens (NovoPen 6, NovoPen Echo Plus), Dose Check, growth hormone pens, and injection needles. Headquartered in Bagsværd, Denmark, and active worldwide.

Company score

Sentiment: 0.10; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.41; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.41; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.78; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.10; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive